pyrazines has been researched along with c-peptide in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (10.34) | 18.2507 |
| 2000's | 8 (27.59) | 29.6817 |
| 2010's | 18 (62.07) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cathelineau, G; Gautier, JF; Jandrain, B; Lacroix, M; Lefèbvre, PJ; Mosora, F; Pirnay, F; Scheen, AJ | 1 |
| Alberti, KG; Berrish, TS; Cooper, BG; Elliott, C; Orskov, H; Reed, JW; Walker, M | 1 |
| Alberti, KG; Farrer, M; Fulcher, GR; Johnson, AS; Walker, M | 1 |
| Belosi, C; Cento, RM; Ciampelli, M; Lanzone, A; Leoni, F; Muzj, G; Romualdi, D | 1 |
| Apa, R; Ciampelli, M; Guido, M; Lanzone, A; Lattanzi, F; Leoni, F | 1 |
| Bjerve, KS; Grill, VE; Mostad, IL; Qvigstad, E | 1 |
| Ackermans, MT; Allick, G; Bisschop, PH; Endert, E; Meijer, AJ; Romijn, JA; Sauerwein, HP; Sprangers, F; Weverling, GJ | 1 |
| Carey, PE; Cline, GW; Cobelli, C; Dalla Man, C; English, PT; Firbank, MJ; Gerrard, J; Taylor, R | 1 |
| Bergman, A; Davies, MJ; De Smet, M; Gottesdiener, KM; Herman, GA; Hilliard, D; Musson, D; Ramael, S; Snyder, K; Stevens, C; Tanaka, W; Tanen, M; Van Dyck, K; Wagner, JA; Wang, AQ; Winchell, G; Yi, B; Zeng, W | 1 |
| Christiansen, JS; Gjedde, S; Gjedsted, J; Gormsen, LC; Jørgensen, JO; Møller, N; Nielsen, S; Vestergaard, ET | 1 |
| Bajaj, M; Cersosimo, E; Cusi, K; Gastaldelli, A; Kashyap, S | 1 |
| Bergman, BC; Cobelli, C; Hunerdosse, DM; Man, CD; Perreault, L | 1 |
| Chisholm, DJ; Douglas, A; Greenfield, JR; Gribble, FM; Holst, JJ; Piyaratna, N; Samocha-Bonet, D; Synnott, EL; Wong, O | 1 |
| Davies, MJ; Goldstein, BJ; Golm, GT; Johnson, J; Kaufman, KD; Teng, R; Williams-Herman, D; Xu, L | 1 |
| Bianchi, L; Bonaventura, A; Carbone, A; Cicero, AF; Derosa, G; Fogari, E; Franzetti, I; Maffioli, P; Querci, F; Romano, D | 1 |
| Ericsson, H; Hompesch, M; Leonsson-Zachrisson, M; Morrow, LA; Norjavaara, E; Sjöberg, F; Sjöstrand, M | 1 |
| Ando, K; Irako, T; Nishimura, R; Sakamoto, M; Tsujino, D; Utsunomiya, K | 1 |
| Aono, M; Fujita, Y; Harashima, SI; Inagaki, N; Koizumi, T; Murata, Y; Ogura, M; Seike, M; Tanaka, D; Wang, Y; Yamane, S | 1 |
| Arai, K; Hirao, K; Hirao, S; Hirao, T; Maeda, H; Sirabe, S; Yamamoto, R; Yamauchi, M | 1 |
| Adams, J; Cersosimo, E; DeFronzo, RA; Garduno-Garcia, Jde J; Solis-Herrera, C; Triplitt, C | 1 |
| Gao, H; Hu, J; Sun, R; Wang, F; Wang, L; Wang, Y; Wang, Z; Yan, S; Yu, X; Zhao, W | 1 |
| Bae, JH; Cho, YM; Jung, HS; Kim, SY; Kim, YG; Oh, TJ; Park, KS | 1 |
| Ahrén, B; Alba, M; Goldstein, BJ; Guan, Y; Inzucchi, SE; Kaufman, KD; Mallick, M; O'Neill, EA; Williams-Herman, DE; Xu, L | 1 |
| Aulinger, BA; Bedorf, A; de Heer, J; Göke, B; Holst, JJ; Kutscherauer, G; Schirra, J | 1 |
| Ferrannini, E; Mari, A; Polidori, D | 1 |
| Gao, Y; Hao, S; Sun, J; Sun, X; Tian, X; Zhang, Z | 1 |
| Apseloff, G; Atiee, G; Bush, MA; Collins, DA; Corsino, L; Feldman, PL; Gillmor, D; McMullen, SL; Morrow, L; Nunez, DJ | 1 |
| Asai, S; Kato, H; Kondo, A; Nagai, Y; Ohta, A; Sada, Y; Sasaoka, T; Tanaka, Y | 1 |
| Aaboe, K; Akram, S; Deacon, CF; Holst, JJ; Krarup, T; Madsbad, S | 1 |
23 trial(s) available for pyrazines and c-peptide
| Article | Year |
|---|---|
Availability of glucose ingested during muscle exercise performed under acipimox-induced lipolysis blockade.
Topics: Administration, Oral; Adult; Blood Glucose; C-Peptide; Calorimetry, Indirect; Carbohydrate Metabolism; Energy Metabolism; Glucagon; Glucose; Glycerol; Humans; Hypolipidemic Agents; Insulin; Lipid Metabolism; Lipolysis; Male; Oxidation-Reduction; Physical Exertion; Pyrazines | 1994 |
The role of plasma non-esterified fatty acids during exercise in type 2 diabetes mellitus.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; C-Peptide; Calorimetry; Carbon Dioxide; Diabetes Mellitus, Type 2; Energy Metabolism; Exercise; Fatty Acids, Nonesterified; Female; Glucagon; Glycerol; Growth Hormone; Humans; Hydroxybutyrates; Hypolipidemic Agents; Insulin; Lactates; Male; Middle Aged; Nitrogen; Oxygen Consumption; Pyrazines; Reference Values | 1993 |
Acipimox increases glucose disposal in normal man independent of changes in plasma nonesterified fatty acid concentration and whole-body lipid oxidation rate.
Topics: Adult; Alanine; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Glucagon; Glucose; Glycerol; Growth Hormone; Humans; Hydroxybutyrates; Hypolipidemic Agents; Insulin; Lactates; Lipid Metabolism; Male; Oxidation-Reduction; Pyrazines; Pyruvates; Radioimmunoassay; Time Factors | 1993 |
Metabolic and endocrine consequences of acute suppression of FFAs by acipimox in polycystic ovary syndrome.
Topics: Adult; Area Under Curve; Body Mass Index; C-Peptide; Fatty Acids, Nonesterified; Female; Glucose Tolerance Test; Growth Hormone-Releasing Hormone; Hormones; Human Growth Hormone; Humans; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipids; Obesity; Polycystic Ovary Syndrome; Pyrazines | 2001 |
A pilot study of the long-term effects of acipimox in polycystic ovarian syndrome.
Topics: Adult; Blood Glucose; C-Peptide; Female; Glucose Tolerance Test; Humans; Hypolipidemic Agents; Insulin; Obesity; Pilot Projects; Polycystic Ovary Syndrome; Pyrazines; Thinness; Time Factors; Triglycerides | 2002 |
Free fatty acids increase hepatic glycogen content in obese males.
Topics: Adult; C-Peptide; Fasting; Fatty Acids, Nonesterified; Gas Chromatography-Mass Spectrometry; Gluconeogenesis; Glucose; Hormones; Humans; Hypolipidemic Agents; Insulin; Liver Glycogen; Male; Middle Aged; Obesity; Pyrazines; Stimulation, Chemical | 2004 |
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
Topics: Administration, Oral; Adolescent; Adult; Analysis of Variance; Area Under Curve; Blood Glucose; C-Peptide; Common Cold; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Eye Diseases; Fasting; Glucagon-Like Peptide 1; Half-Life; Headache; Humans; Insulin; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2005 |
Free fatty acids decrease circulating ghrelin concentrations in humans.
Topics: Adult; Anticoagulants; Blood Glucose; C-Peptide; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Ghrelin; Glucose Clamp Technique; Heparin; Human Growth Hormone; Humans; Hydrocortisone; Hyperinsulinism; Hypolipidemic Agents; Insulin; Male; Peptide Hormones; Pyrazines; Somatostatin | 2006 |
Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes.
Topics: Adult; Blood Glucose; C-Peptide; Circadian Rhythm; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Genetic Predisposition to Disease; Glucose Clamp Technique; Hormones; Humans; Hyperglycemia; Hypolipidemic Agents; Insulin; Insulin Secretion; Male; Osmolar Concentration; Pyrazines; Time Factors | 2007 |
Incretin action maintains insulin secretion, but not hepatic insulin action, in people with impaired fasting glucose.
Topics: Aged; Blood Glucose; Body Mass Index; C-Peptide; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Humans; Hyperglycemia; Incretins; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Liver; Male; Middle Aged; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Triazoles | 2010 |
Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients.
Topics: Administration, Oral; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glutamine; Humans; Hyperglycemia; Insulin; Insulin Secretion; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.
Topics: Blood Glucose; C-Peptide; C-Reactive Protein; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Fasting; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Italy; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males.
Topics: Adult; Azetidines; Benzamides; Body Mass Index; C-Peptide; Cross-Over Studies; Enzyme Activators; Epinephrine; Glucagon; Glucokinase; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Norepinephrine; Pyrazines; Sulfones; Young Adult | 2012 |
Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).
Topics: Adamantane; Adult; Aged; Biomarkers; Blood Glucose; C-Peptide; Cross-Over Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Japan; Male; Middle Aged; Monitoring, Ambulatory; Natriuretic Peptide, Brain; Nitriles; Pilot Projects; Plasminogen Activator Inhibitor 1; Postprandial Period; Predictive Value of Tests; Pyrazines; Pyrrolidines; Serum Albumin; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Vildagliptin | 2012 |
Efficacy and safety of switching from basal insulin to sitagliptin in Japanese type 2 diabetes patients.
Topics: Aged; Asian People; Body Mass Index; Body Weight; C-Peptide; Demography; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male; Pyrazines; ROC Curve; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2013 |
Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucagon; Glucagon-Secreting Cells; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Middle Aged; Pioglitazone; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Female; Gastric Emptying; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin Secretion; Male; Middle Aged; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles | 2014 |
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Insulin-Secreting Cells; Least-Squares Analysis; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiophenes; Time Factors; Triazoles | 2014 |
Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Mesylates; Metformin; Middle Aged; Oxadiazoles; Peptide YY; Prognosis; Pyrazines; Receptors, G-Protein-Coupled; Sitagliptin Phosphate; Triazoles | 2014 |
Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
Topics: C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Up-Regulation | 2015 |
6 other study(ies) available for pyrazines and c-peptide
| Article | Year |
|---|---|
Acute lowering of circulating fatty acids improves insulin secretion in a subset of type 2 diabetes subjects.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Dietary Proteins; Energy Intake; Exercise; Fasting; Fatty Acids; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hyperglycemia; Hypertriglyceridemia; Insulin; Insulin Secretion; Male; Middle Aged; Obesity; Proinsulin; Pyrazines | 2003 |
Acute inhibition of lipolysis does not affect postprandial suppression of endogenous glucose production.
Topics: Adult; Blood Glucose; C-Peptide; Fatty Acids, Nonesterified; Female; Food; Glucagon; Glucose; Glycerol; Humans; Hypolipidemic Agents; Insulin; Kinetics; Lipolysis; Liver; Magnetic Resonance Spectroscopy; Male; Middle Aged; Oxidation-Reduction; Placebos; Pyrazines; Triglycerides | 2005 |
Effect of combined therapy of human Wharton's jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic rats.
Topics: Animals; C-Peptide; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Streptozocin; Treatment Outcome; Triazoles; Umbilical Cord | 2014 |
Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes.
Topics: Adamantane; Blood Glucose; Body Mass Index; C-Peptide; Creatinine; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Insulin Resistance; Male; Middle Aged; Multivariate Analysis; Nitriles; Pyrazines; Pyrrolidines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
Lansoprazole enhances the antidiabetic effect of sitagliptin in mice with diet-induced obesity and healthy human subjects.
Topics: Adult; Animals; Area Under Curve; Blood Glucose; C-Peptide; Diet; Drug Synergism; Drug Therapy, Combination; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Lansoprazole; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes.
Topics: Administration, Oral; Aged; Algorithms; Biomarkers; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Fatty Acids, Nonesterified; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Glargine; Insulin-Secreting Cells; Insulin, Long-Acting; Japan; Male; Proinsulin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |